Filing Flows › Royalty Pharma (RPRX) › Guidance history
Royalty Pharma (RPRX) guidance history: what it guided and what it reported
Royalty Pharma gave guidance in 2 earnings releases on file since Aug 5, 2026. Its releases raised guidance once and lowered it 0 times.
Revenue
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2017 | $1.3B (Nov 4, 2026) | — | — | — |
The latest quarter
Royalty Pharma, Q3 2026: revenue $690M (+13% year over year), operating margin 59.5%, net earnings $145M, operating cash flow $686M. The chart follows the revenue to costs, profit and cash.
Questions
Does Royalty Pharma beat its guidance?
Royalty Pharma gave guidance in 2 earnings releases on file since Aug 5, 2026. Its releases raised guidance once and lowered it 0 times.
How often does Royalty Pharma raise guidance?
Its earnings releases raised guidance once and lowered it 0 times since Aug 5, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.